Drugs / Previfenon®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04446065 | Sep 2020 → Sep 2021 | COVID-19 | MELISA Institute Genomics & Proteomics Research SpA | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Previfenon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04446065 ↗ |
| Modality | Small molecule | “a biologically active polyphenol extracted and purified from Camellia Sinensis” NCT04446065 ↗ |